Tokyo, Japan

Shingo Dan

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Iwate Medical University, Japanese Foundation for Cancer Research, Nagasaki University. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shingo Dan. Retrieved from https://idiyas.com/inventor/shingo-dan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shingo Dan: Innovator in Cancer Treatment

Introduction

Shingo Dan is a prominent inventor based in Tokyo, Japan. He is recognized for his significant contributions to the field of cancer treatment, particularly through his innovative research on tyrosine kinase inhibitors.

Latest Patents

Shingo Dan holds a patent for a fourth-generation EGFR tyrosine kinase inhibitor. This compound exhibits specific inhibitory activity against the C797S resistant mutant EGFR, which is particularly relevant for treating non-small cell lung cancer that has developed resistance due to this mutation. His work provides a promising avenue for developing targeted therapies for patients facing this challenging condition.

Career Highlights

Throughout his career, Shingo Dan has worked with esteemed institutions such as Nagasaki University and Iwate Medical University. His research has focused on advancing the understanding and treatment of cancer, making him a valuable asset in the medical research community.

Collaborations

Shingo Dan has collaborated with notable colleagues, including Masatomo Iwao and Tsutomu Fukuda. These partnerships have contributed to the advancement of his research and the development of innovative solutions in cancer treatment.

Conclusion

Shingo Dan's work in developing a specific tyrosine kinase inhibitor showcases his dedication to improving cancer therapies. His contributions are vital in the ongoing fight against cancer, particularly for patients with resistant mutations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…